Federated Hermes’s UroGen Pharma URGN Stock Holding History

Federated Hermes’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$35.3K	Buy	+958	New	+$26K	﹤0.01%	1734
2026 Q1	–	Sell	-196	Closed	-$4.59K	–	2167
2025 Q4	$4.59K	Buy	196 +64	+48%	+$1.39K	﹤0.01%	1900
2025 Q3	$2.63K	Buy	+132	New	+$2.37K	﹤0.01%	2006
2024 Q1	–	Sell	-11,709	Closed	-$176K	–	2135
2023 Q4	$176K	Sell	11,709 -1,421	-11%	-$18.4K	﹤0.01%	1529
2023 Q3	$184K	Buy	+13,130	New	+$211K	﹤0.01%	1534
2018 Q4	–	Sell	-6	Closed	-$1K	–	2314
2018 Q3	$1K	Buy	+6	New	+$279	﹤0.01%	2220

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Federated Hermes's URGN Position: Q2 2026 in Review

Federated Hermes opened a new position in UroGen Pharma (URGN) in Q2 2026: 958 shares worth $35.3K. The stake represents ﹤0.01% of the portfolio and ranks #1734 among its holdings. This is a return to the name: Federated Hermes previously reported a position in URGN as recently as Q4 2025.

Federated Hermes first reported a position in URGN in Q3 2018 and has held it in 6 quarters since. The position peaked at $184K in Q3 2023. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Federated Hermes held 958 shares of UroGen Pharma worth $35.3K as of Q2 2026.
UroGen Pharma was a new Federated Hermes position in Q2 2026.
UroGen Pharma made up ﹤0.01% of Federated Hermes's portfolio in Q2 2026, its #1734 holding.
Federated Hermes first reported a position in UroGen Pharma in Q3 2018 and has held it in 6 quarters since.
Federated Hermes's UroGen Pharma position peaked at $184K in Q3 2023.
189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.